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Abstract
Background: The aim of this study was to assess, the efficacy and safety of add-on corticosteroids to antiretroviral
therapy [ART] in patients with biopsy proven HIV associated nephropathy.
Methods: All included patients had histological evidence of either collapsing or non-collapsing focal segmental
glomerulosclerosis (FSGS) or podocyte and/or parietal cell hypertrophy or hyperplasia. All patients had evidence of
tubulointerstitial inflammation with microcysts. Patients were randomized to ART with the addition of 1 mg/kg of
corticosteroids [ART+C] or remained in the group [ART Alone] and followed for 2 years. A repeat biopsy was performed
at 6months.
Results: Twenty-one patients were randomized to [ART+C] and 17 to [ART Alone]. The baseline estimated glomerular
filtration rate (eGFR) was significantly lower in the [ART+C] vs. [ART Alone] group [35mls/min/1.73m2 vs. 47 mls/min/
1.73m2, p = 0.015]. The [ART+C] cohort had a statistically significant improvement in median (eGFR) from baseline to
last follow up compared with [ART Alone] i.e. [Δ = 25mls/min (IQR: 15;51) vs 9 mls/min (IQR: 0–24), p = 0.008].
There were no statistically significant differences between the groups when proteinuria and histology were analyzed.
There were 8 deaths during the trial period, 7 from [ART+C] (Log rank p = 0.071).
Conclusions: In the [ART+C] cohort there was a significant improvement in eGFR over 2-years with increased mortality.
Routine corticosteroid use cannot currently be recommended. Further investigation to define which subgroup of this
cohort would safely benefit from the positive effects is required.
Trial registration: ISRCTN study ID (56112439] was retrospectively registered on the 5 September 2018.
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Background
Despite the era of antiretroviral therapy [ART], human
immunodeficiency virus [HIV]–related kidney disease
still carries a significant risk of end-stage renal disease
(ESRD) [1]. From available data in Africa the prevalence
of chronic kidney disease (CKD) in HIV-infected pa-
tients is reported to be 38% in Nigeria [2], 33.5% in
Zambia [3], 20% in Uganda [4], 11.5% in Kenya [5], and
5.5–6% in South Africa [6, 7]. The regional variations in
CKD prevalence is likely due to differences in reporting
methods, sampling, definition of CKD, access to health
care and genetic factors [8].
The recent [Kidney Disease Improving Global Out-
comes] KDIGO Controversies Conference publication, en-
dorsed a pathological classification of HIV-related kidney
diseases. The classification encompassed glomerular-,
tubulointerstitial- and vascular-dominant lesions as well
as other lesions seen in the setting of HIV [9]. Classic HIV
associated nephropathy [HIVAN] is defined as a collapsing
glomerulopathy with interstitial inflammation, microcysts
and tubular injury [9]. The interstitial component includes
a diffuse inflammatory cell infiltrate which may include
plasma cells [8, 10–13]. Numerous studies describe the re-
lease of several inflammatory mediators e.g. interleukin 6,
nuclear factor kappa B [14] and transforming growth fac-
tor β [15]. These mediators promote interstitial inflamma-
tion and subsequent fibrosis [14, 16, 17].
Mortality is reduced when initiating antiretroviral
therapy [ART] in patients with HIVAN [11, 18]. How-
ever despite ART improving mortality and renal impair-
ment there are still a subgroup of patients where CKD
progresses regardless of ART [11]. This may be ex-
plained by the kidneys acting as a viral reservoir for HIV
nucleic acid, even on ART [19–21].
A number of old studies have evaluated the efficacy and
safety of corticosteroids in the treatment of classic HIVAN
[22–24]. However, these studies were limited by their
retrospective, non-randomized design together with differ-
ent ART and steroid regimens. There has also been safety
concerns due to increased risk of infections [18]. To the
best of our knowledge only one retrospective study of 19
patients has assessed the use of corticosteroids for the
treatment of HIVAN in the triple therapy era of ART and
demonstrated a significant improvement in estimated
glomerular filtration rate [eGFR] in the corticosteroid arm
[24]. Further trials to assess corticosteroid benefit have
therefore been recommended [18, 21].
The aim of our study was to assess the balance be-
tween improvement in eGFR, proteinuria and adverse
events with adjuvant corticosteroids to ART in patients
with HIVAN. Our hypothesis was that there would be a
greater improvement in eGFR in the corticosteroid co-
hort due to the dampening effect of inflammation in the
interstitial compartment in those patients with HIVAN.
The importance is underscored by the high prevalence
of CKD in HIV positive patients in Africa and the lack
of prospective treatment studies.
Methods
This was a prospective, open labelled trial to investigate
the response to corticosteroids as adjuvant treatment to
ART in patients with glomerular and interstitial features
of HIVAN. The study was approved by the Human Re-
search Ethics Committee of the University of Cape Town
[HREC:241/2007]. The trial was registered with the
ISRCTN registry [ISRCTN study ID (56112439].
Study population
HIV positive patients (defined by a positive Elisa test)
with unexplained renal impairment, proteinuria and/or
haematuria underwent renal biopsy as per best clinical
practice for the period [April 2010–May 2015]. Inclusion
criteria for the study included all ART naïve patients
with histologically proven HIVAN. This was defined as
1) collapsing glomerulopathy 2) focal segmental glomer-
ulosclerosis or 3) podocyte hypertrophy and/or hyper-
plasia plus all biopsies required the presence of chronic
tubulointerstitial inflammation with plasma cells, lym-
phocytes and microcysts. Further inclusion criteria in-
cluded age > 18 years, written informed consent, no prior
ART exposure (ART naïve) or newly initiated on ART
for less than 2 weeks prior to renal biopsy; and initiation
of ART within one-month post biopsy. Exclusion criteria
included any active infection (including Kaposi sarcoma
and active cytomegalovirus), eGFR of < 10ml/min/
1.73m2 and an inability to follow up at our centre.
Study outcomes
The primary outcome was to assess, in patients with
HIVAN, the change in eGFR and proteinuria between
the [ART+C] and [ART Alone] cohorts from baseline to
24months. Secondary outcomes were to monitor for ad-
verse events and to review whether there was improve-
ment in histology; specifically podocytopathy, interstitial
fibrosis, lymphocytic and plasma cell infiltration from
baseline. In consented patients, comparisons were made
with a repeat renal biopsy at 6 months.
Treatment regimen
We allocated consecutive patients to ART plus cortico-
steroids [ART + C] or [ART Alone]. Consecutive pa-
tients were assigned their treatment by randomly
selecting a sealed opaque envelope with the treatment
allocation. Both investigator and patients were not
blinded during the study period as additional prophylac-
tic treatment was required to prevent opportunistic in-
fections in those receiving [ART+C]. The ART regimen
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used in the trial was determined by the Department of
Health policy on ART roll-out during the study period.
Patients in the [ART+C] arm were commenced on 1
mg/kg of prednisone within 2 weeks of starting ART
(maximum dose was 60mg/day irrespective of body
weight). Where patients had tuberculosis [TB] and were
on rifampicin at the start of the study, prednisone dose
was increased to 1.5 mg/kg with a maximum dose of 90
mg/day. Prednisone was tapered over a 6-month period
by 10 mg per month. Treatment with angiotensin con-
verting enzyme inhibition (ACEi) or angiotensin recep-
tor blockade (ARB) was also commenced in those
patients whose BP would allow and where hyperkalae-
mia was not a complication. Isoniazid and cotrimoxazole
was started in the [ART+C] group for TB and pneumo-
cystis jirovecii prophylaxis.
Baseline measurements
At baseline, demographic features (age, gender, and ethni-
city), clinical features including weight, systolic and dia-
stolic blood pressures (SBP and DBP), renal function;
serum creatinine (μmol/L), eGFR (mL/min/1.73m2), and
urine protein/creatinine ratio (uPCR)(gm/mmol), CD4
count (cells/mm3),HIV viral load (log10cps/ml), haemo-
globin (Hb)(g/dL) and cholesterol (mmol/L) were ob-
tained and documented. In keeping with our centre’s
protocol for assessing patients with glomerular patholo-
gies, various serological markers were also assessed and
included anti-nuclear antibody, anti-double-stranded
DNA, RPR, hepatitis B and C, anti-streptolysin titre,
anti-DNase B titre and total complement assays (C3 and
C4) to exclude other forms of kidney disease. All variables
were obtained within 2 weeks of the renal biopsy. The
eGFR was calculated according to the Chronic Kidney Dis-
ease Epidemiology Collaboration [CKD-EPI] eq. [25]
Follow-up visits
Patients were followed up monthly for 6 months and
then every 3months for 2 years. At each visit the follow-
ing assessments were performed: blood pressure (BP),
serum creatinine, eGFR, Hb and uPCR. Serum choles-
terol, viral load and CD4 counts were measured every 3
months. Mortality data was obtained from death certifi-
cates, patient folders, records from HIV clinics and fam-
ily members.
Histology
An initial renal biopsy was performed in all participating
patients and the obtained specimen was processed for
light microscopy with haematoxylin and eosin (H&E),
methenamine silver and periodic acid-Schiff (PAS)
stains. Standard techniques were performed to demon-
strate IgA, IgM, IgG and C3 for immunohistochemistry
and electron microscopy. A single histopathologist [MD]
and nephrologist [NW] reviewed all biopsies. The biop-
sies were reviewed for glomerular or tubulointerstitial
features of HIVAN as described in the inclusion criteria.
The degree of interstitial fibrosis, lymphocytic infiltrate
in the interstitium and amount of microcysts present in
the interstitium were graded from 0 to 4 according to
the following grading system [0 < 5%; 1 = 5–25%; 2 = 26–
50%; 3 = 51–75%; 4 > 75%.] The percentage of plasma
cells within the lymphocytic infiltrate was graded 0–4
[0 = 0; 1 < 5%; 2 = 6–15%; 3 = 16–30% and 4 > 30%.] An
upper limit of the plasmacytic infiltrate was 30%, as be-
yond this the infiltrate may have been considered part of a
lymphoproliferative disorder. The presence or absence of
podocyte and parietal cell hypertrophy and hyperplasia
was determined [0 = none, 1 = present]. In consenting pa-
tients, a repeat renal biopsy was performed to assess histo-
logical changes at 6months. An interval change was
interpreted as “improving” if there was a reduction in the
grading seen at repeat biopsy. The assessment of repeat
histology was blinded to the histopathologist [MD] and
nephrologist [NW].
Statistics
Data was analysed using Stata version 14.2 (Stata Cor-
poration, College Station, TX). Missing variables for fol-
low up eGFR and uPCR were imputed using last
observation carried forward for all patients who died or
were lost to follow up in the trial period. Any patient
with less than 3 months follow up data was excluded
from the final analysis. Continuous variables were sum-
marised as medians with interquartile range [IQR], while
categorical variables were summarised using frequencies
and proportions. Continuous variables were compared
using the Wilcoxon rank-sum test, and categorical data
was compared using Fisher’s exact test.
A LOESS smoothing function was used to describe the
relationship between follow-up time on ART and eGFR,
stratified by steroid treatment. A smooth curve was gen-
erated through the scatter plot using locally weighted
regression.
Multivariable linear regression analyses was per-
formed to analyse the association between change in
eGFR and uPCR, and treatment between [ART+C]
and [ART Alone] when adjusted for known and po-
tential confounders including age, gender and ACEi/
ARB treatment.
Fisher’s Exact test used to compare baseline histo-
logical features between groups. Histological change
from baseline to repeat biopsy was categorised into “im-
proving” versus “no change” or “worsening” according to
the original histological grading as described in the
methods. Fisher’s exact test was used to compare binary
histological change (yes/no) at repeat biopsy between
[ART + C] and [ART Alone].
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A Kaplan-Meier survival curve was used to illustrate
survival probability for [ART + C] and [ART Alone] in
all patients. Log-rank test was used to compare survival
curves between treatment groups. The results with p <
0.05 were interpreted as statistically significant where
appropriate.
Results
A total of 1131 renal biopsies were performed during
the trial period. Of these, 354 [31.3%] were from
HIV-infected patients (Fig. 1: Study flowsheet for the
trial). All patients had a clinical indication for biopsy.
There were 38 patients who met criteria for inclusion
into the trial; of these, 21 patients (55.3%) were treated
with [ART+C] while 17 patients (44.7%) were treated
with [ART Alone]. Table 1 describes the baseline charac-
teristics of the cohort.
Overall, there were more females (65.8%), median age
was 33 (IQR: 25–39) years, median SBP and DBP was
118 (110–125) mmHg and 77 (71–83) mmHg, respect-
ively. All patients included in the trial were of black Af-
rican ethnic origin. Only one patient (2.6%) had diabetes
while 7 [18.4%] were known with hypertension. There
were ten patients (26.3%) who were diagnosed with TB
at time of presentation. Patients were initiated on an
ACE-I or ARB if their BP could tolerate it and if hyper-
kalaemia was not a complication. Overall 71.1% of pa-
tients were treated with an ACE-I or ARB ([ART +C]
14/21 and [ART Alone] 12/17). All patients received
triple regimen ART therapy. The most common initial
ART regimen [52.6%] consisted of stavudine (D4T),
lamivudine (3TC) and efavirenz (EFV) /nevirapine
(NEV). The other ART combinations are detailed in
Table 1; no patient received tenofovir.
There were 2 variables that were significantly different
between the groups. The first was median eGFR which
was lower in the [ART+C] arm [35mls/min/1.73m2 vs.
47 mls/min/1.73m2, p = 0.015]. The second was median
age where the [ART Alone] group was younger [28 yrs.
vs 36 yrs., p = 0.050](Table 1). All serological markers
tested to exclude other causes of kidney disease were
negative. The baseline histological features are outlined
in Table 2. There were no statistically significant differ-
ences histologically between the groups.
Changes in clinical and biochemical parameters from
baseline until last follow–up
All patients were analyzed as per intention to treat for
the primary outcome. Additional file 1 Table S1 includes
all changes in median CD4 and viral load at 3-,6-, 12-
and 24-months. Over the study period the eGFR im-
proved in both the groups (Fig. 2: eGFR by duration on
ART with and without the addition of corticosteroids.)
Figure 3 describes the median eGFR and IQR at 6, 12-
and 24-month periods. The group receiving [ART+C]
had a statistically significant improvement in median
eGFR from baseline to last follow-up compared with
[ART Alone] i.e. [Δ = 25mls/min (IQR: 15–51) vs 9 mls/
min (IQR: 0–24), p = 0.008] (Table 3).
Additional file 2 Table S2 describes all eGFR values at
baseline and last follow-up. Proteinuria improved in both
groups over the trial period however the change in pro-
teinuria was not statistically significant between the
Fig. 1 Study flow chart for the trial
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groups. [(ART+C) Δ = − 0.13 g/mmol (− 0.25;-0.08) versus
(ART Alone) Δ = − 0.12 g/mmol (− 0.55;0.06) p = 0.691]
(Table 3). There was no clinically significant change in BP,
Hb, cholesterol or albumin over the trial period.
Table 4 demonstrates the multivariable linear regres-
sion analysis for change in eGFR and uPCR at 24
months. After adjustment for baseline eGFR, age, ACEi
and sex the change in eGFR with the addition of cortico-
steroids from baseline to 24 months trended towards sig-
nificance (β coefficient: 18.63 ml/min/1.73 m2, 95% CI
[− 2.26–39.52]; (p = 0.078) (Table 4). There was no asso-
ciation observed for change in uPCR (β coefficient: 0.09
g/mmol, 95% CI -0.19-0.33); (p = 0.525) over the study
period.
Histological changes from baseline to repeat renal biopsy
After 6 months, 21/38 (55%) patients consented to and
underwent a repeat renal biopsy. Interval changes in
histology are recorded in Table 5. There was no statisti-
cally significant difference in histological progression for
any feature between the 2 groups.
Adverse events
There were 2 cases of herpes zoster that occurred be-
tween 10 and 14 days after commencing [ART + C].
Both cases were treated without sequelae. There were
8 deaths that occurred during the 24-month trial
period, 1 from the group [ART Alone] and 7 from
those treated with corticosteroids [ART+C] (Log rank
p = 0.071) [Fig. 4: Kaplan Meier: Mortality [ART + C]
vs [ART Alone]]. One death occurred in the first
month in the group [ART Alone] as a result of TB.
In the group [ART+C]: 1 patient died in the first
month of the trial of unknown cause, 3 patients died
of sepsis within the first 7 months of the trial and the









Gender (female), n[%] 25 [65.8%] 14 [66.7%] 11 [64.7%] 0.899a
Age (years) median IQR 33 [2;39] 36 [27;42] 28 [25;34] 0.050b
Clinical parameters
Systolic BP (mmHg) median [IQR] 118 [110;125] 118 [110;125] 118 [110;121] 0.668b
Diastolic BP (mmHg median [IQR] 77 [71;83] 76 [65;80] 77 [71;84] 0.561b
Diabetes; n [%} 1 [2.6%] 1 [4.8%] 0 1.000a
Hypertension, n [%} 7 [18.4%] 5 [23.8%] 2 [11.8%] 0.306a
Tuberculosis at baseline, n [%} 10 [26.3] 7 [33.3%] 3 [17.6%] 0.242a
Commenced on ACE/ARB; n [%} 27 [71.1%] 14 [66.7%] 12 [70.6%] 0.519a
ART regimen at baseline, n [%} 0.332a
- D4T/3TC/EFV or NEV 20 [52.6%] 11 [52.4%] 9 [52.9%]
- ABC/3TC/EFV or NEV 9 [23.7%] 7 [33.3%] 2 [11.8%]
- ZVD/3TC/EFV or NEV 6 [15.8%] 2 [9.5%] 4 [23.5%]
- Other/unknown 3 [7.9%] 1 [4.8%] 2 [11.8%]
Biochemical parameters
eGFR (ml/min/1.73m2) median[IQR] 43.5 [26;70] 35 [18;46] 47 [39;97] 0.015b
eGFR (ml/min/1.73m2) mean [SD] 50 [32.8] 37.8 [26.0] 65.1 [34.8]
CD4 (cells/mm3) median[IQR] 158 [63;309] 158 [36;272] 173 [104;352] 0.437b
HIV VL (Log 10) (cps/ml) median[IQR] 4.77 [3.87;5.29] 4.77 [4.5;5.29] 4.69 [2.75;5.3] 0.5623b
Albumin (g/L) median[IQR] 30 [25;33] 29 [24;32] 30.5 [27;36] 0.262b
uPCR (g/mmol) median[IQR] 0.36 [0.14;0.54] 0.43 [0.17;0.52] 0.23 [0.13;0.60] 0.617b
Haemoglobin (g/dL) median[IQR] 8.1 [7.3;10.2] 8.0 [7.4;9.9] 8.1 [7.3;10.2] 0.872b
Cholesterol(mmol/l) median[IQR] 4.5 [3.6;5.6] 4.4 [3.3;5.1] 4.8 [3.9;6.0] 0.347b
ART + C Antiretrovirals + corticosteroids, ART Alone Antiretrovirals alone, IQR interquartile range, BP Blood pressure, ACEi angiotensin converting enzyme inhibitor,
ARB angiotensin receptor blocker, D4T Stavudine, 3TC Lamivudine, NEV Nevirapine, ABC Abacavir, EFV Efavirenz, ZVD Zidovudine, uPCR urine protein-to-creatinine
ratio, HIV VL HIV viral load, eGFR estimated glomerular filtration rate, SD standard deviation. a = Fishers Exact test, b =Wilcoxon Rank-Sum test, * p-value comparison of
[ART+C] vs [ART Alone]
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other 3 patients died after completing corticosteroids.
[See Additional file 3 Table S3].
Discussion
Our study is the first open labelled prospective trial in
Africa to assess the effect of corticosteroids on kidney
function in patients with HIVAN treated at a single
centre in Cape Town, South Africa. Important observa-
tions from this study include the following: (i) a signifi-
cant increase in eGFR in patients treated with
corticosteroids (without a significant reduction in pro-
teinuria at last follow up) (ii) increased adverse events
including risk of infections and all-cause mortality in the
group treated with ART and adjuvant corticosteroids,
and (iii) reduced interstitial inflammation seen on repeat
biopsy in both arms without a significant difference be-
tween the groups.
Previous studies have demonstrated a positive effect of
corticosteroids on kidney function in patients with bi-
opsy proven HIVAN [22–24]. In a study of 20 patients
with HIVAN on dual ART therapy with oral prednisone,
Smith et al. reported a reduction of serum creatinine as
well as a significant reduction of proteinuria [22]. How-
ever, relapses were reported when prednisone was
Table 2 Baseline histological features
Histological features Total (%) ART + C (%) ART Alone (%) P Valuea
N = 38 N = 21 N = 17
Classic HIVAN 68.4% 66.7% 70.6% 0.791
FSGS [NOS] with tubulointerstitial inflammation and microcysts 26.3% 33.3% 17.6% 0.268
Podocytopathy with tubulointerstitial inflammation and microcysts 5.3% 0% 11.8% 0.103
Interstitial disease
Lymphocytic infiltration[grading]
0 5.3% 4.8% 5.9% 0.799
1 34.2% 8.6% 41.2%
2 26.3% 23.8% 29.4%
3 21.1% 28.6% 11.8%
4 13.2% 14.3% 11.8%
Plasmacytic infiltration[grading]
0 5.3% 4.8% 5.9% 0.533
1 28.9% 28.6% 29.4%
2 18% 9.5% 29.4%
3 13.2% 19.0% 5.9%
4 34.2% 38.1% 29.4%
Interstitial fibrosis [grading]
0 5.3% 0% 11.8% 0.389
1 28.9% 14.3% 35.3%
2 15.8% 14.3% 11.8%
3 36.8% 23.8% 29.4%
4 13.1% 4.8% 11.8%
Microcysts [grading]
0 31.6% 23.8% 41.2% 0.698
1 28.9% 33.3% 23.5%
2 28.9% 33.3% 23.5%
3 10.5% 9.5% 11.8%
4 – – –
ART + C Antiretrovirals + corticosteroids, ART Alone Antiretrovirals alone, FSGS Focal segmental glomerulosclerosis, NOS Not otherwise specified
Microcysts, lymphocytic infiltrate and fibrosis in the interstitium was graded 0–4: [0 < 5%; 1 = 5–25%; 2 = 26–50%; 3 = 51–75%;4 > 75%] The percentage of plasma
cells within the lymphocytic infiltrate was graded [0 = 0; 1 < 5%; 2 = 6–15%; 3 = 16–30% and 4 > 30%]
Podocytes and parietal cell hypertrophy/hyperplasia were graded 0 = absent; 1 = present
a = the Fisher’s exact test used to compare baseline histological features between groups
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tapered and six patients developed serious infections on
prednisone, with 11 reported deaths [22]. In another
study of 21 patients, 12 of which were treated with pred-
nisone, Eustace et al reported an 80% reduction in risk
of ESRD, but a higher risk of infections in the treatment
group [23]. Only one retrospective study of 19 patients
has assessed the use of corticosteroids in the triple ther-
apy era of ART. The 5 patients who received prednisone
experienced an increase in creatinine clearance of 5.57
ml/min/1.73 m2 per month (p = 0.003) [24].
The rational for the corticosteroid regimen used in
our trial was based on the dosing schedule used to
treat drug induced acute interstitial nephritis [AIN] as
well as a regimen similar to that used by Smith et al.
for steroid use in HIVAN [22, 26]. The tapering
period was lengthened to a gradual taper over 6
months as the average length of time for HIV viral
suppression after initiation of ART is 3–6 months
[27–29]. The working hypothesis was that improving
interstitial inflammation would improve renal
Fig. 2 eGFR by duration on ART with and without the addition of corticosteroids. Footnote. LOESS smoothing function with 95% confidence interval
Fig. 3 Box and whisker plot representing the median eGFRs with IQRs at 6, 12- and 24-month periods
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function. Since HIV is the cause of interstitial inflam-
mation in HIVAN it was important to allow enough
time for the HIV to be controlled prior to cessation
of the steroids.
This study demonstrates a positive improvement in
eGFR in those receiving [ART + C] compared with those
on [ART Alone] [Δ = 25mls/min (IQR: 15–51) vs 9 mls/
min (IQR: 0–24), p = 0.008]. However, when the multi-
variable linear regression model was adjusted for base-
line eGFR, although the change in eGFR over the study
period was no longer significant the β coefficient [18.63]
still demonstrated an improvement compared to ART
alone. The lack of statistical significance is likely due to
small numbers and the marked discrepancy of baseline
eGFR between the two cohorts. Although proteinuria
improved there was no statistical significant difference
between the groups. On interval analysis, inflammation
improved in both groups. Interstitial inflammation is a
prominent histopathologic component of HIVAN [9,
11]. Inflammation may lead to interstitial fibrosis which
is strongly correlated with poor renal prognosis in many
forms of CKD including HIVAN [11, 30, 31]. .The lack
of additional improvement of corticosteroids on protein-
uria while improving eGFR may point to a benefit in
dampening down the interstitial inflammatory response.
The renal biopsy may have been performed too early
and the sample size too small to see a significant re-
sponse to those treated with corticosteroids.
There were 10 cases of TB identified prior to trial ini-
tiation. There were no further cases documented
throughout the trial. Those with TB continued and com-
pleted their course of treatment. There were adverse
events documented in the trial. There were 2 cases of
herpes zoster treated without sequelae, 2 weeks after
commencing ART and corticosteroids. There were
deaths occurring in the early trial period in both groups
with more deaths occurring in the corticosteroid arm.
This could not be explained by differences in CD4 count
or viral load suppression between the groups. [See Add-
itional file 1 Table S1] This raises the question of a sig-
nificant contributory effect of corticosteroids to sepsis in
these patients.
However in contrast to our findings, a study conducted
in South Africa using corticosteroids for the adjuvant
treatment of tuberculous pericarditis used substantially
higher doses of steroids [32]. This study had high numbers
of HIV-infected patients and demonstrated a significant
reduction in the incidence of constrictive pericarditis
with no increased risk of mortality in those patients
receiving corticosteroids. The trial did however dem-
onstrate an increase in HIV associated cancers a find-
ing not observed in our study [32]. The results of our
Table 4 Multivariable linear regression analysis for Change in eGFR and uPCR at 24 months
Δ in eGFR (ml/min/1.73m2) at 24 months Δ in UPCR (gm/mmol) (at 24 months
β Coefficient (95%CI) P = value β Coefficient (95% CI) P = value
On steroids 18.63 [−2.26–39.52] 0.078 0.09 [−0.19–0.37] 0.525
Baseline eGFR −0.16 [− 0.47–0.16] 0.317 0.00 [− 0.00–0.01] 0.695
Age 0.37 [− 0.59–1.33] 0.435 0.01 [0.00–0.03] 0.031
ACE inhibition −2.63 [− 23.48–18.21] 0.798 − 0.08 [− 0.36–0.20] 0.574
Sex, female −9.67 [− 29.06–9.71] 0.316 0.11 [− 0.15–0.37] 0.384
Estimated glomerular filtration rate [eGFR], urine protein creatinine ratio [uPCR], angiotensin converting enzyme [ACE], confidence interval [CI]
Table 3 The change [Δ] in clinical and biochemical parameters at 24 months
Median change [Δ] in parameters at 24 months [IQR] [ART + C] [ART Alone] P Valuea
Clinical parameters
Systolic BP mmHg [IQR] 10 [−25; 11] 6 [2; 18] 0.466
Diastolic BP mmHg [IQR] −6 [−20;4] 1 [−5; 7] 0.177
Biochemical parameters
Change in eGFR (ml/min/1.73m2) [IQR] 25 [15;51] 9 [0;24] 0.008
Change in uPCR (gm/mmol) [IQR] −0.13 [−0.25; −0.08] −0.12 [−0.55; −0.06] 0.691
Change in Haemoglobin (gm/dL)[IQR] 3.4 [0.3; 4.7] 3.6 [2.1; 4.8] 0.480
Change in Albumin (gm/L)[IQR] 5 [2; 12] 6 [4;15] 0.445
Change in Cholesterol (mmol/l)[IQR] 0.2 [−0.10; 1.7] 0.3 [−1.5; 0.9] 0.577
ART + C Antiretrovirals + corticosteroids, ART Alone Antiretrovirals alone, BP Blood pressure, eGFR estimated glomerular filtration rate, uPCR protein creatinine ratio,
a = Wilcoxon Rank-Sum test
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Lymphocytic infiltration 50.0% 55.6% 1.000
0 4.8% 0.0% 5.9% 22.2%
1 8.6% 58.3% 41.2% 44.4%
2 23.8% 33.3% 29.4% 33.3%
3 28.6% 8.3% 11.8% 0.0%
4 14.3% 0.0% 11.8% 0.0%
Plasma cell infiltration 75% 44.4% 0.203
0 4.8% 8.3% 5.9% 11.1%
1 28.6% 25.0% 29.4% 66.7%
2 9.5% 41.7% 29.4% 11.1%
3 19.0% 25.0% 5.9% 11.1%
4 38.1% 0.0% 29.4% 0.0%
Interstitial fibrosis 75.0% 44.4% 0.203
0 0.0% 0.0% 11.8% 33.3%
1 14.3% 50.0% 35.3% 44.4%
2 14.3% 41.7% 11.8% 22.2%
3 23.8% 8.3% 29.4% 0.0%
4 4.8% 0.0% 11.8% 0.0%
Microcysts 41.8% 22.2% 0.642
0 23.8% 50.0% 41.2% 77.7%
1 33.3% 50.0% 23.5% 11.1%
2 33.3% 0.0% 23.5% 11.1%
3 9.5% 0% 11.8% 0%
4 0.0% 0% 0% 0%
ART + C Antiretrovirals + corticosteroids, ART Alone Antiretrovirals alone, a = Fisher’s Exact Test to compare improvements in histology on repeat biopsy
between groups
Fig. 4 Kaplan Meier: Mortality [ART + C] vs [ART Alone]
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trial suggest the need to reconsider the dose and dur-
ation of corticosteroid therapy. However, given that
renal replacement therapy is rationed or limited in
many regions of Africa the positive effect seen on
kidney function needs to be balanced against the like-
lihood of sepsis and mortality.
There were several limitations of the study. Firstly, the
sample size was small and the baseline eGFR was
significantly lower in the corticosteroid arm. The
randomization process used was via sealed envelope, al-
though not ideal, was strictly adhered to. This highlights
the need for a larger study defining hard endpoints of
eGFR and proteinuria improvements with stratification
into eGFR subgroups, to improve the validity of the re-
sults. Secondly patients and clinicians were not blinded
to those who received corticosteroids, however the rea-
son for this was additional opportunistic prophylaxis
was required for this group. Thirdly at the start of this
study there was no consensus on the histological defin-
ition of HIVAN. Fourthly, the length of time of follow
up for the cohort was 24 months. For meaningful renal
survival data, a longer follow up time period would be
necessary. Lastly, pill counts were not used to assess
compliance on corticosteroids.
Conclusions
Despite the observed improvement in eGFR in patients
treated with corticosteroids, our study cannot currently
justify the use of corticosteroids at 1 mg/kg with tapering
over 6 months to treat patients with biopsy proven
HIVAN due to the increased mortality seen. Given the
lack of effect on proteinuria it is postulated that the
positive effect on eGFR may be having an impact on the
interstitial component seen in HIVAN. Future longitu-
dinal studies need to be directed to understanding those
patients most likely to benefit from corticosteroid ther-
apy while identifying those at higher risk for septic
events. A lower corticosteroid dose, shorter duration of
therapy and closer follow up may improve outcomes in
this patient group.
Additional files
Additional file 1: Table S1. CD4 count values and viral load non-
suppression between baseline and 24 months. (DOCX 30 kb)
Additional file 2: Table S2. Baseline and last follow-up eGFR for all
patients. (DOCX 32 kb)
Additional file 3: Table S3. Adverse Events. (DOCX 29 kb)
Abbreviations
3TC: Lamivudine; ACEi: Angiotensin converting enzyme inhibition;
ARB: Angiotensin receptor blockade tuberculosis (TB); ART + C: Antiretroviral
therapy plus corticosteroids; ART: Antiretroviral therapy; CD4: Cluster of
differentiation [cells/mm3] cells per millimeter cubed; CKD: Chronic kidney
disease; CKDepi: Kidney disease epidemiology collaboration; D4T: Stavudine;
DBP: Diastolic blood pressure; EFV: Efavirenz; eGFR: Estimated glomerular
filtration rate; ESRD: End-stage renal disease; g/dl: Grams per deciliter;
H&E: Haematoxylin and eosin; HIV: Human immunodeficiency virus;
HIVAN: HIV associated nephropathy; IQR: Interquartile range; KDIGO: Kidney
disease improving global outcomes; Mg: Milligrams; Mmol/L: Millimoles per
litre; PAS: Periodic acid-Schiff; SBP: SYSTOLIC blood pressure; TB: Tuberculosis;
uPCR: Urine protein creatinine ratio; μmol/L: Micromoles per litre
Acknowledgements
Michael Schomaker for his contribution to the LOESS smoothing function
and graph generation (Fig. 2).
Funding
There was no funding obtained for the trial. It was performed in the HIV
renal clinical at Groote Schuur Hospital.
Availability of data and materials
Data can be obtained on request by contacting nicola.wearne@uct.ac.za
Authors’ contributions
1. Conceived and/or designed the work that led to the submission, acquired
data, and/or played an important role in interpreting the results. 2. Drafted
or revised the manuscript. 3. Approved the final version. NW [1–3], CRS [1–3],
MSD [1, 3], BD [1–3], KM [1–3], BR [1–3],NT [1–3], AB [1, 2], PN [1], IO [1–3]. All
authors have read and approved the manuscript.
Ethics approval and consent to participate
1. The study was approved by the Human Research Ethics Committee of the
University of Cape Town South Africa reference no: [HREC:241/2007]: Written
and verbal informed consent was obtained from all participants.
2. Inclusion criteria [Included in methods section]: included written informed
consent and translated into Isixhosa where necessary by an interpreter; if the
participant did not speak English then an interpreter was obtained and
verbally explained the informed consent].
Consent for publication
There are no images or videos relating to an individual person therefore
consent for publication is not required.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Division of Nephrology and Hypertension, Groote Schuur Hospital,
University of Cape Town, Cape Town, South Africa. 2Kidney and
Hypertension Research Unit, University of Cape Town, Cape Town, South
Africa. 3Division of Pathology, Department of Clinical Laboratory Services,
University of Cape Town, Cape Town, South Africa. 4Department of Medicine,
Statistical Analyst, University of Cape Town, Cape Town, South Africa. 5CIDER:
School of Public Health and Family Medicine, University of Cape Town, Cape
Town, South Africa. 6Department of Undergraduate Medicine, University of
Cape Town, Cape Town, South Africa.
Received: 6 August 2018 Accepted: 9 January 2019
References
1. Campos P, Ortiz A, Soto K. HIV and kidney diseases: 35 years of history and
consequences. Clin Kidney J. 2016;9(6):772–81.
2. Emem CP, Arogundade F, Sanusi A, Adelusola K, Wokoma F, Akinsola A.
Renal disease in HIV-seropositive patients in Nigeria: an assessment of
prevalence, clinical features and risk factors. Nephrol Dial Transplant. 2008;
23(2):741–6.
3. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, et al. Baseline
renal insufficiency and risk of death among HIV-infected adults on
antiretroviral therapy in Lusaka, Zambia. AIDS. 2008;22(14):1821.
Wearne et al. BMC Nephrology           (2019) 20:44 Page 10 of 11
4. Peters PJ, Moore DM, Mermin J, Brooks JT, Downing R, Were W, et al.
Antiretroviral therapy improves renal function among HIV-infected
Ugandans. Kidney Int. 2008;74(7):925–9.
5. Wools-Kaloustian K, Gupta SK, Muloma E, Owino-Ong’or W, Sidle J, Aubrey
RW, et al. Renal disease in an antiretroviral-naive HIV-infected outpatient
population in Western Kenya. Nephrol Dial Transplant. 2007;22(8):2208–12.
6. Han T, Naicker S, Ramdial P, Assounga A. A cross-sectional study of HIV-
seropositive patients with varying degrees of proteinuria in South Africa.
Kidney Int. 2006;69(12):2243–50.
7. Fabian J, Naicker S, Goetsch S, Venter WDF. The clinical and histological
response of HIV-associated kidney disease to antiretroviral therapy in south
Africans. Nephrol Dial Transplant. 2013;28(6):1543–54.
8. Diana NE, Naicker S. Update on current management of chronic kidney
disease in patients with HIV infection. Int J Nephrol Renov Dis. 2016;9:223.
9. Swanepoel CR, Atta MG, D’Agati VD, Estrella MM, Fogo AB, Naicker S, et al.
Kidney disease in the setting of HIV infection: conclusions from a kidney
disease: improving global outcomes (KDIGO) controversies conference.
Kidney Int. 2018;93(3):545–59.
10. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al. The
clinical epidemiology and course of the spectrum of renal diseases
associated with HIV infection. Kidney Int. 2004;66(3):1145–52.
11. Wearne N, Swanepoel CR, Boulle A, Duffield MS, Rayner BL. The spectrum of
renal histologies seen in HIV with outcomes, prognostic indicators and
clinical correlations. Nephrol Dial Transplant. 2012;27(11):4109–18.
12. Rao TK, Filippone EJ, Nicastri AD, Landesman SH, Frank E, Chen CK, et al.
Associated focal and segmental glomerulosclerosis in the acquired
immunodeficiency syndrome. N Engl J Med. 1984;310(11):669–73.
13. D'Agati V, Suh JI, Carbone L, Cheng JT, Appel G. Pathology of HIV-associated
nephropathy: a detailed morphologic and comparative study. Kidney Int.
1989;35(6):1358–70.
14. Ross MJ, Fan C, Ross MD, Chu T-H, Shi Y, Kaufman L, et al. HIV-1 infection
initiates an inflammatory cascade in human renal tubular epithelial cells. J
Acquir Immune Defic Syndr. 2006;42(1):1–11.
15. Yamamoto T, Noble NA, Miller DE, Gold LI, Hishida A, Nagase M, et al.
Increased levels of transforming growth factor-&bgr; in HIV-associated
nephropathy. Kidney Int. 1999;55(2):579–92.
16. Weiner NJ, Goodman JW, Kimmel PL. The HIV-associated renal diseases:
current insight into pathogenesis and treatment. Kidney Int. 2003;63(5):
1618–31.
17. Bruggeman LA, Nelson PJ. Controversies in the pathogenesis of HIV-
associated renal diseases. Nat Rev Nephrol. 2009;5(10):574–81.
18. Yahaya I, Uthman OA, Uthman MMB. Interventions for HIV-associated
nephropathy. Cochrane Database Syst Rev. 2009:CD007183.
19. Marras D, Bruggeman LA, Gao F, Tanji N, Mansukhani MM, Cara A, et al.
Replication and compartmentalization of HIV-1 in kidney epithelium of
patients with HIV-associated nephropathy. Nat Med. 2002;8(5):522.
20. Canaud G, Dejucq-Rainsford N, Avettand-Fenoël V, Viard J-P, Anglicheau D,
Bienaimé F, et al. The kidney as a reservoir for HIV-1 after renal
transplantation. J Am Soc Nephrol. 2014;25(2):407–19.
21. Cohen SD, Kopp JB, Kimmel PL. Kidney diseases associated with human
immunodeficiency virus infection. N Engl J Med. 2017;377(24):2363–74.
22. Smith MC, Austen JL, Carey JT, Emancipator SN, Herbener T, Gripshover B, et al.
Prednisone improves renal function and proteinuria in human
immunodeficiency virus-associated nephropathy. Am J Med. 1996;101(1):41–8.
23. Eustace JA, Nuermberger E, Choi M, Scheel PJ, Moore R, Briggs WA. Cohort
study of the treatment of severe HIV-associated nephropathy with
corticosteroids. Kidney Int. 2000;58(3):1253–60.
24. Szczech L, Edwards L, Sanders L, Van der Horst C, Bartlett J, Heald A, et al.
Protease inhibitors are associated with a slowed progression of HIV-related
renal diseases. Clin Nephrol. 2002;57(5):336–41.
25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A
new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;
150(9):604–12.
26. González E, Gutiérrez E, Galeano C, Chevia C, de Sequera P, Bernis C, et al.
Early steroid treatment improves the recovery of renal function in patients
with drug-induced acute interstitial nephritis. Kidney Int. 2008;73(8):940–6.
27. O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, et al.
Durability of viral suppression with first-line antiretroviral therapy in patients
with HIV in the UK: an observational cohort study. Lancet HIV. 2017;4(7):
e295–302.
28. Giuliano M, Guidotti G, Andreotti M, Pirillo MF, Villani P, Liotta G, et al. Triple
antiretroviral prophylaxis administered during pregnancy and after delivery
significantly reduces breast milk viral load: a study within the drug resource
enhancement against AIDS and malnutrition program. J Acquir Immune
Defic Syndr. 2007;44(3):286–91.
29. Study EC. Time to undetectable viral load after highly active antiretroviral
therapy initiation among HIV-infected pregnant women. Clin Infect Dis.
2007;44(12):1647–56.
30. Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in
patients with biopsy-proven lupus nephritis. Nephrology. 2010;15(4):482–90.
31. Okpechi IG, Dlamini TA, Duffield M, Rayner BL, Moturi G, Swanepoel CR.
Outcome of patients with primary immune-complex type Mesangiocapillary
glomerulonephritis (MCGN) in Cape Town south Africa; 2014.
32. Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F, et al.
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.
N Engl J Med. 2014;371(12):1121–30.
Wearne et al. BMC Nephrology           (2019) 20:44 Page 11 of 11
